Niagen Bioscience (NAGE) Operating Leases (2019 - 2026)

Niagen Bioscience (NAGE) has 8 years of Operating Leases data on file, last reported at $2.6 million in Q1 2026.

• Operating Leases for Q1 2026 came in at $2.6 million, down 26.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.6 million (down 26.03% YoY), and the FY2025 annual result was $1.8 million, down 30.19% from the prior year.
• Operating Leases advanced to $2.6 million in Q1 2026 per NAGE's latest filing, from $1.8 million in the prior quarter.
• Over five years, Operating Leases peaked at $4.6 million in Q1 2022 and troughed at $1.8 million in Q4 2025.
• A 5-year average of $3.4 million and a median of $3.3 million in 2023 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2022 and 2024: Operating Leases soared 221.23% in 2022, then tumbled 42.54% in 2024.
• A 5-year view of Operating Leases shows it stood at $3.5 million in 2022, then decreased by 6.75% to $3.3 million in 2023, then decreased by 21.21% to $2.6 million in 2024, then slumped by 30.19% to $1.8 million in 2025, then surged by 43.25% to $2.6 million in 2026.
• Business Quant data shows NAGE's Operating Leases at $2.6 million in Q1 2026, $1.8 million in Q4 2025, and $3.1 million in Q3 2025.